# Synergistic Combinations One of the strongest reasons to track Urolithin A is that it may matter more as a sensitising adjunct than as a stand-alone compound. ### Special report {% hint style="info" %} #### Featured cross-link [**Hydroxychloroquine + Boswellia**](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/hydroxychloroquine-+-boswellia.md) now also matters in the Urolithin A section. That report explains why **Urolithin A** is drawing attention as a possible way to offset some of **HCQ's** healthy-tissue mitochondrial burden while preserving the broader autophagy-blocking logic. The rationale is mechanistically strong, but still hypothetical. Direct combination data is still missing. {% endhint %} ### Gemcitabine Pancreatic-cancer models have shown encouraging combination signals with gemcitabine. The proposed logic includes stronger suppression of survival signalling and improved pressure on resistant tumour biology. This remains preclinical. ### Anti-PD-1 therapy Preclinical pancreatic-cancer work has also suggested improved anti-tumour immune activity when Urolithin A is paired with anti-PD-1 therapy. That fits with the wider immune story around mitochondrial fitness and T-cell function. It does not yet prove clinical benefit in patients. ### Checkpoint-inhibitor trial relevance A current clinical trial is assessing Urolithin A in patients receiving immune checkpoint inhibitors. That does not make the combination established. It does show that the combination logic is considered serious enough to test in humans. ### Drug-efflux and resistance biology Another combination angle comes from ABCG2-related signalling. If that biology proves clinically meaningful, it could help explain why Urolithin A keeps appearing in treatment-sensitisation discussions. ### Hormone-sensitive disease Because Urolithin A has selective estrogen-receptor-modulating signals, combination logic in ER-positive disease needs more caution. That area is biologically interesting, but not yet settled enough for confident combination claims. ### Bottom line The combination story for Urolithin A is one of its main strengths. Right now, that story is still mostly mechanistic and preclinical. It supports further study, not casual self-designed combination protocols. ### In this section * [Overview](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/anticancer-mechanisms.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/immune-effects.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/synergistic-combinations.md) * [Urolithin A Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type.md) * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/safety-and-interactions.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/dosing-and-timing.md) * [Sourcing Quality Urolithin A](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sourcing-quality-urolithin-a.md) * [Sensitisation to Conventional Therapies](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sensitisation-to-conventional-therapies.md) * [Antimicrobial, Antiviral & Terrain Support](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/antimicrobial-antiviral-and-terrain-support.md) ### Key References Urolithin A in pancreatic cancer models and combination research\ Checkpoint-inhibitor combination trial listing\ Urolithin A research overview and oncology applications\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/synergistic-combinations.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.